|
 |
Oriģinālais nosaukums |
|
|
Tirdzniecības nosaukumi ir apzīmējoši un palīgvielas var atšķirties dažādām valstīm un laboratorijām
|
|
Accofil |
Beļģija, Horvātija, Lielbritānija, Vācija |
|
Duperan |
Čīle |
|
Filgen |
Argentīna, Čīle |
|
Foltran |
Čīle |
|
Granulokine |
Brazīlija, Grieķija, Itālija |
|
Hebervital |
Kolumbija |
|
Inmunef |
Kolumbija, Meksika |
|
Leucosos |
Kolumbija |
|
Lioplim |
Čīle |
|
Neupogen |
Amerikas Savienotās Valstis, Apvienotie Arābu Emirāti, Austrālija, Austrija, Beļģija, Čīle, Dānija, Ēģipte, Ekvadora, Francija, Holande, Irāna, Īrija, Jaunzēlande, Kanāda, Kolumbija, Lielbritānija, Luksemburga, Malaizija, Maroka, Meksika, Norvēģija, Polija, Portugāle, Saūda Arābija, Slovēnija, Somija, Spānija, Šveice, Turcija, Vācija, Venecuēla, Zviedrija |
|
Neutromax |
Argentīna |
|
Neutropine |
Argentīna |
|
Nivestim |
Beļģija, Francija, Holande, Lielbritānija, Norvēģija, Vācija |
|
Ratiograstim |
Austrija, Lielbritānija, Vācija, Zviedrija |
|
Tevagrastim |
Beļģija, Brazīlija, Čīle, Holande, Horvātija, Lielbritānija, Norvēģija, Spānija, Šveice, Vācija, Zviedrija |
|
|
 |
 |
Literatūras saraksts : Filgrastim |
|
|
tips |
publicēšana |
| 99 |
Žurnāls |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 104 |
Žurnāls |
Hall PD, Yui D, Lyons S, Bosso JA.
Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 185-189. |
| 182 |
Žurnāls |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Žurnāls |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 2269 |
Žurnāls |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 3128 |
Laboratorija |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013 |
| 3249 |
Žurnāls |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3256 |
Žurnāls |
Burnett B, Radic I.
Stability of Hospira filgrastim following changes to thermal and photic storage conditions.
EJHP 2011 ; 17, 5: 49-56. |
| 3474 |
Laboratorija |
Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009 |
| 3618 |
Laboratorija |
Filgrastim (Neupogen®) - Summary of Product Characteristics
Amgen 2014 |
| 3828 |
plakāts |
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015 |
| 3829 |
plakāts |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015 |
| 4055 |
Žurnāls |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4380 |
Laboratorija |
Posaconazole (Noxafil®) - Summary of Product Characteristics
Merck Sharp & Dohme Limited 2019 |
| 4471 |
Laboratorija |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019 |
| 4521 |
Žurnāls |
Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B.
Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.
Pharmaceutical Technology in Hospital Pharmacy 2020 |
| 4650 |
Laboratorija |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021 |
|
|
